$AMD

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Dynatrace, Five Below, Fortune Brands, Klarna Group, Jersey Mike’s Subs, Moderna, Sherwin-Williams, and More

Wall Street analysts issued updates on several companies. AMD was upgraded to Strong Buy with a $641 target, while Five Below was downgraded to Hold. Bitcoin continued its rally, trading near $79,420. Investors await Fed comments and inflation data.

Original reporting
Published Aug 25, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 2:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Dynatrace, Five Below, Fortune Brands, Klarna Group, Jersey Mike’s Subs, Moderna, Sherwin-Williams, and More — source image
Decision brief

The 30-second read

$AMDBullishMed
01

Why it matters

Collective analyst rating changes provide fresh signals for short-term positioning, though overall market sentiment remains mixed ahead of Fed commentary.

02

Market read

Analyst rating shifts can trigger immediate price moves, especially for high‑profile names like AMD and SHW.

03

What to watch

Potential macro headwinds from upcoming Fed data could dampen enthusiasm despite upgrades.

Relevance 5/10Novelty 5/10Timing: today

Background

Daily analyst research roundup highlighting upgrades, downgrades, and initiations across various US-listed stocks.

Company-level read

Ticker impact

$AMDBullishMedium confidence
Context

Upgraded to Strong Buy from Outperform with price target raised to $641.

Expected impact

Potential short-term upside of 3-5% on news flow.

Evidence & confidence

Upgrade from a reputable house with a higher target suggests near-term buying pressure.

$BFHBullishMedium confidence
Context

Upgraded to Outperform from Peer Perform with $130 target.

Expected impact

Modest upside of 1-2% expected.

Evidence & confidence

Target increase modest; market may price in gradually.

$DTBullishMedium confidence
Context

Upgraded to Overweight from Equal Weight, target raised to $65.

Expected impact

Potential 2-4% rally.

Evidence & confidence

Higher weight and target suggest bullish sentiment.

$MRNABullishLow confidence
Context

Raised to Peer Perform from Underperform, no target change.

Expected impact

Limited upside, 1-2% move.

Evidence & confidence

Rating lift without target indicates modest sentiment shift.

$FOURBullishMedium confidence
Context

Upgraded to Overweight from Equal Weight, target $59.

Expected impact

Potential 2-3% gain.

Evidence & confidence

Higher weight and target may attract short-term buying.

$FISBearishMedium confidence
Context

Downgraded to Equal Weight from Overweight, target $46.

Expected impact

Possible 2-4% decline.

Evidence & confidence

Downgrade suggests weaker expectations.

$FIVEBearishLow confidence
Context

Downgraded to Hold from Buy, target unchanged at $250.

Expected impact

Minor downside pressure.

Evidence & confidence

Hold rating may temper momentum.

$KLARBearishLow confidence
Context

Downgraded to Peer Perform from Outperform, no target.

Expected impact

Potential modest pullback.

Evidence & confidence

Rating cut without target suggests limited impact.

Market effects

Broad analyst activity may lift sentiment across tech, fintech, and consumer discretionary sectors.

US market focus; limited direct regional effect.

Minor global impact; primarily US equity investors.

Counterpoint

Some upgrades may be premature given macro uncertainty; caution on short-term trades.

Key entities

  • Raymond James

    Upgraded AMD to Strong Buy.

  • Wolfe Research

    Provided multiple upgrades/downgrades.

  • Morgan Stanley

    Upgraded Dynatrace.

Related articles

$MRNAMed

Moderna stock rises 8%: can it continue its cancer vaccine success rally?

Moderna's stock rose 8% after positive Phase 3 results for its personalized mRNA cancer vaccine, intismeran autogene, in combination with Merck's Keytruda. The trial showed improved recurrence-free survival in high-risk melanoma patients. Analysts have raised price targets, with Argus setting a $180 target. Moderna's stock has gained over 100% in the past month. Merck may also benefit from increased Keytruda demand.

$MRNAMed

Why Are Moderna (MRNA) Shares Soaring Today

Moderna (MRNA) shares rose 7.1% after a positive presentation at the Morgan Stanley Global Healthcare Conference. Investors reacted to progress in its cancer vaccine trial and regulatory approvals in its respiratory portfolio. The stock is up 404% year-to-date but remains 10.8% below its 52-week high.

$AMDHigh

Why is Advanced Micro Devices stock rallying today?

Advanced Micro Devices (AMD) stock rose 4.3% to $534.47 after Piper Sandler reiterated an Overweight rating and $600 target, citing strong demand for CPUs and GPUs. AMD's Q3 revenue guidance is $13 billion, with the semiconductor industry projected to grow significantly by 2030. The broader market also gained post-Fed rate hike.

$AMDHighAI 8/10

Jim Cramer on Advanced Micro Devices (AMD): “Buy It”

Jim Cramer endorsed Advanced Micro Devices (AMD) on Mad Money, citing its strong performance and growth potential. AMD reported Q2 revenue of $11.5B, with Data Center revenue up 107% YoY. The company guided for Q3 revenue of ~$13B. AMD is expanding into rack-scale AI systems, but faces execution and AI spending risks. Hedge fund ownership rose to 164 in Q2, with short interest around 2.5%.